Our policy on cancer drugs

We believe that all cancer patients in the UK should be able to access the best, evidence-based drugs available for their condition. 

The Government must balance the need to spend the health budget carefully with the need to guarantee access to effective drugs. It must also create the right incentives for industry to produce innovative new medicines.

Regulators must ensure that only drugs that are safe and that work will reach patients as quickly as possible.

It is a time of great change in this area, with the introduction of new arrangements for commissioning and paying for chemotherapy in England  in 2013. In different parts of the UK, policy makers and bodies such as the NICE and the Scottish Medicines Consortium are developing new approached to providing access to medicines.

We work to ensure that government policy helps cancer patients to access the drugs they need.

Reports

Cancer patients’ views on government plans to introduce value-based pricing for medicines

August 2011

Download report [PDF]

Consultations

Response to NHS England and NICE consultation on Cancer Drugs Fund reform

February 2016

Download Response [PDF]

Response to the NHS England consultation on revisions to the Standard Operating Procedures for the Cancer Drugs Fund

October 2014

Download Response [PDF]

Response to NICE review of the methods for Technology Appraisal

June 2014

Download Response [PDF]

Response to NICE review of the guide to the processes of Technology Appraisal 

March 2014

Download response [PDF]

Consultation on revisions to the statutory scheme for medicines pricing

July 2013

Download response [PDF]

Cancer Drugs Fund: a consultation

January 2011

Download response [PDF]

Commissioned research brief

Access to chemopreventative drugs (January 2016)

Initial expressions of interest by 28th January 2016

Download [PDF]PDF icon

Contact us

Get in touch with our policy team to find out more information about our policy on access to cancer treatments.

Call our policy team for more information.

020 3469 8360 

Email the team

Share this page